BIOCSL today released A
Clinician’s Guide to Australian
Venomous Bites and Stings:
incorporating the updated CSL
Antivenom Handbook.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 19 Mar 13 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Mar 13
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).